Strategically Comprehensive Immunotherapy Employing Modified Antibody Targeting NY-ESO-1 for Multiple Myeloma

被引：0
|
作者：
Maruta, Masaki [1 ]
Tanimoto, Kazushi [1 ]
Azuma, Taichi [1 ]
Fujiwara, Hiroshi [1 ]
Yasukawa, Masaki [1 ]
机构：
[1] Ehime Univ, Sch Med, Dept Int Med 1, Matsuyama, Ehime, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
Immune cell therapy; Multiple myeloma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2374
引用
收藏
页码：757 / 757
页数：1
相关论文
共 50 条
  • [31] Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
    Zhou, Hong
    Ma, Yipeng
    Liu, Fenglan
    Li, Bin
    Qiao, Dongjuan
    Ren, Peigen
    Wang, Mingjun
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [32] A Potential Role for Immunotherapy in Thyroid Cancer by Enhancing NY-ESO-1 Cancer Antigen Expression
    Gunda, Viswanath
    Frederick, Dennie T.
    Bernasconi, Maria J.
    Wargo, Jennifer A.
    Parangi, Sareh
    THYROID, 2014, 24 (08) : 1241 - 1250
  • [33] Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer
    Saito, Takuro
    Kurkawa, Yukinori
    Fujitani, Kazumasa
    Kawabata, Ryohei
    Takeno, Atsushi
    Mikami, Jota
    Endo, Shunji
    Matsuyama, Jin
    Akamaru, Yusuke
    Hirota, Masashi
    Kishi, Kentaro
    Tanaka, Koji
    Takahashi, Tsuyoshi
    Wada, Hisashi
    Eguchi, Hidetoshi
    Doki, Yuichiro
    CANCER SCIENCE, 2025, 116 : 488 - 488
  • [34] NY-ESO-1 antigen-antibody interaction process based on an TFBG sensor
    Qu, Hang
    Tan, Linyao
    Wu, Fang-cai
    Huang, Weiyuan
    Li, Kaiwei
    Chen, Xiaoyong
    Xu, Yi-wei
    Hu, Xuehao
    BIOMEDICAL OPTICS EXPRESS, 2023, 14 (11) : 5921 - 5931
  • [35] Development of T-Cell Therapy By Exploiting Modified Antibodies Specific for A2/NY-ESO-1 for Refractory Myeloma
    Maruta, Masaki
    Ochi, Toshiki
    Tanimoto, Kazushi
    Azuma, Taichi
    Fujiwara, Hiroshi
    Yasukawa, Masaki
    BLOOD, 2017, 130
  • [36] NY-ESO-1 specific CD4+ Thelper1 cells for immunotherapy of cancer
    Kayser, Simone
    Boss, Cristina
    Schumm, Michael
    Feucht, Judith
    Stevanovic, Stefan
    Lang, Peter
    Handgretinger, Rupert
    Garbe, Claus
    Roecken, Martin
    Feuchtinger, Tobias
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Screening for NY-ESO-1 expression as a cancer immunotherapy target in soft-tissue sarcoma
    Sellner, L.
    Chudasama, P.
    Gdynia, G.
    Renner, M.
    Heilig, C.
    Egerer, G.
    Ho, A. D.
    Shiku, H.
    Mechtersheimer, G.
    Froehling, S.
    Schmitt, M.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S41 - S42
  • [38] NY-ESO-1 specific antibodies are frequently detected in hight-risk myeloma.
    van Rhee, F
    Szmania, SM
    Pomtree, M
    Zhan, F
    Moreno, A
    Rosen, N
    Fox, M
    Barlogie, B
    Shaughnessy, J
    Batchu, R
    Tricot, GJ
    BLOOD, 2004, 104 (11) : 676A - 676A
  • [39] NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
    van Rhee, F
    Szmania, SM
    Zhan, FH
    Gupta, SK
    Pomtree, M
    Lin, P
    Batchu, RB
    Moreno, A
    Spagnoli, G
    Shaughnessy, J
    Tricot, G
    BLOOD, 2005, 105 (10) : 3939 - 3944
  • [40] Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
    Liu, Xin
    Xu, Yixiang
    Xiong, Wei
    Yin, Bingnan
    Huang, Yuqian
    Chu, Junjun
    Xing, Changsheng
    Qian, Chen
    Du, Yang
    Duan, Tianhao
    Wang, Helen Y.
    Zhang, Ningyan
    Yu, John S.
    An, Zhiqiang
    Wang, Rongfu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
12345